Peroxitech is developing a novel peptide lead candidate, PIP-2, aimed at preventing and treating acute lung injury by modulating a NOX2‑related oxidative injury signaling pathway. The peptide has shown broad protection and rescue in multiple preclinical models, protecting cells from injury and enabling recovery to near‑normal levels. The company was seeded and incubated at Xontogeny in 2021 and was launched via the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures. Peroxitech has secured follow‑on grants from the National Institutes of Health to support additional indications and pipeline development. The company plans to use proceeds from its recent financing to complete IND‑enabling studies and advance PIP‑2 into clinical development. Leadership includes CEO and co‑founder Thomas Han, with Sheldon Feinstein, Ph.D., and Aron Fisher, M.D. as co‑founders; Xontogeny executives serve on the board. Peroxitech Therapeutics is developing PIP-2, a peptide delivered into the lungs to prevent the cytokine storm cascade that leads to respiratory failure in acute lung injury (ALI). PIP-2 targets a newly identified early pathway involving peroxiredoxin 6 (Prdx6) to reduce reactive oxygen species buildup in the lung. Preclinical studies cited by the company show prevention of moderate-to-severe ALI when dosed prophylactically, near-complete rescue when dosed 12 hours after onset, and improved survival in ALI caused by COVID-19. The company plans to use seed funding to complete IND-enabling work, including pharmacokinetics studies and additional toxicology preclinical trials. Peroxitech positions PIP-2 as a potential breakthrough modality beyond current lung-protective ventilation approaches and aims to advance the product into the clinic as quickly as possible. The company has formed a board including its CEO and representatives from its seed investor to support development and execution.

Total raised

$25M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2022